不同剂量恩度联合顺铂腔内灌注治疗非小细胞肺癌恶性胸腔积液患者疗效及不良反应的差异

摘要

目的:对非小细胞肺癌(non-small cell lung cancer,NSCLC)恶性胸腔积液患者接受不同剂量恩度联合顺铂腔内灌注治疗的疗效以及不良反应情况进行观察分析.方法:选取非小细胞肺癌恶性胸腔积液患者60例,时间为2014年1月至2015年8月,简单随机化法分为两组,均给予恩度与顺铂联合进行腔内灌注治疗,其中对照组给予顺铂40 mg· m-2 dl和恩度45 mg d2,实验组给予顺铂40 mg.m-2 dl和恩度45 mg d2、d5.结果:实验组NSCLC伴MPE患者疾病缓解率(76.67％)、疾病控制率(90.00％)明显高于对照组的疾病缓解率(50.00％)、疾病控制率(66.67％),P＜0.05;实验组不良反应发生情况与对照组不良反应情况相比,差异较小,P＞0.05.结论:非小细胞肺癌恶性胸腔积液患者接受高剂量恩度联合顺铂腔内灌注治疗的疗效好,毒副反应未增加,临床应根据患者的具体病情以及耐受情况,选择合理的剂量为患者实施治疗,促进其预后的改善.%Objective:To analysis the curative effect and adverse reactions of non-small cell lung cancer with malignant pleural effusion patients received different doses,Endostar combined with cisplatin intracavity perfusion.Methods:60 patients with non-small cell lung cancer with malignant pleural effusion,in January 2014-August 2015,were divided into 2 groups using a simple method of randomization,both to give grace and cisplatin plus intracavity perfusion therapy,the control group given cisplatin 40 mg· m-2 dl and Endostar 45 mg d2 and experimental group cisplatin for a 40 mg· m-2 dl and Endostar 45 mg d2,d5.Results:Experimental group disease remission rate (76.67％),disease control rates (90.00％) is significantly higher than control group in disease remission rate (50.00％),disease control rates (66.67 ％),P ＜ 0.05;Difference of adverse reactions between two groups is small,P ＞ 0.05.Conclusion:Curative effect of high dose Endostar combined with cisplatin is better for Non-small cell lung cancer with malignant patients,and the adverse reactions don't increase.It should be based on the specific patient and tolerance to choose reasonable dose for patients with treatment to promote the improvement of the prognosis.